Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a combination of two active pharmaceutical ingredients: losartan, an angiotensin II receptor blocker (ARB), and isosorbide mononitrate (ISMN), an organic nitrate. Losartan works by selectively blocking the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced blood pressure, and decreased aldosterone secretion. Isosorbide mononitrate acts as a nitric oxide donor; it relaxes vascular smooth muscle predominantly in veins but also in arteries, reducing cardiac preload and afterload. The combination may be used experimentally or off-label for additive antihypertensive effects or management of certain cardiovascular conditions such as hypertension with coexisting angina pectoris. There are no widely marketed fixed-dose products containing both agents together; use would typically involve co-prescription of individual drugs[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on losartan + isosorbide mononitrate.